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A Comparison of Systolic Blood Pressure in Women With and Without 
 Lymphedema Following Surgery for Breast Cancer 
Deborah M. Arvidson-Hawkins 
ABSTRACT 
There is no evidenced-based research on prevention of upper extremity 
lymphedema following breast cancer treatment. General guidelines have been identified 
from a basic understanding of the lymphatic system and are considered to be prudent 
advice for prevention. Cause of lymphedema is hypothesized to be multifactorial and 
time of onset is widely varied. Exogenous risk factors leading to lymphedema are the 
removal and destruction of lymph nodes; however, not all women develop lymphedema 
following axillary lymph node dissection. Co-morbid conditions such as obesity, 
diabetes, and hypertension are cited as possible endogenous risk factors. Several studies 
identify hypertension as a significance endogenous risk factor resulting in increased 
capillary filtration causing an increase in the fluid load on an already compromised 
lymph drainage system. This retrospective chart review was designed to compare systolic 
blood pressure in two matched groups to determine if there is a difference between 
groups. The study population included 147 stage II and III breast cancer patients. After 
receiving IRB approval, charts of patients with a diagnosis code of 
 v  
lymphedema (n=19) were identified from the 147 possible charts. A matching sample of 
18 women without lymphedema was assembled. Vital sign records were then reviewed 
and 3 measures of systolic blood pressure were used from a time period of two to 15 
moths after lymph node dissection. Results revealed mean age and number of lymph 
nodes removed in the two groups were equivalent. No significant difference in systolic 
blood pressure was found between the two groups. However, he study was limited by the 
lack of chart data on the variables of lymphedema and systolic blood pressure This pilot 
study pointed out adjustments needed to capture a more diverse sample. Other limitations 
such as missing demographic data on race, number of participants treated with radiation 
to the axilla and records of ambulatory blood pressure should be included in future 
studies.
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Chapter I 
Introduction 
As part of the surgical treatment and staging of breast cancer, axillary lymph 
nodes that drain the breast are removed. When choosing the best adjuvant treatment for 
individual patients, an important factor to consider is the number of lymph nodes 
involved with cancer. Axillary lymph node status is an important prognostic factor for 
patients with breast cancer; however, this procedure is associated with considerable 
morbidity (National Comprehensive Cancer Network [NCCN], 2005). Lymphedema is 
among the most visible side effects after treatment for breast cancer. Lymphedema can 
occur in any quadrant drained by the affected nodal bed leading to truncal edema, breast 
edema or upper extremity edema (Muscari, 2004). The surgical technique of sentinel 
lymph node biopsy has been shown to be an effective alternative to complete axillary 
lymph node dissection for staging of breast cancer. However, if sentinel lymph nodes are 
found to be involved with cancer, a complete axillary node dissection is necessary 
(NCCN, 2005). Lymphedema is a condition that can be treated and managed over a 
lifetime but cannot be cured.  Problems associated with lymphedema are pain, 
discomfort, disability, alteration in body image, and difficulty fitting clothing (Ridner, 
2002).  
The number of reported occurrences of lymphedema varies widely; this may be 
due to the fact that definition and measurement vary substantially among studies. A study 
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done by Kwan et al. (2002) reported approximately 50% of patients screened were 
symptomatic and 12.5% of those screened had measurable lymphedema. Petrek, Senie, 
Peters, and Rosen (2001) reported that approximately 400,000 women cope with 
lymphedema on a daily basis. In another clinical study on incidence and risk, one in five 
of the study sample developed lymphedema. Of those women, 80% developed 
lymphedema by one year post surgery (Clark & Harlow, 2005). In a cohort study over a 
twenty-year time period, Petrek, et al. (2001) found that out of 263 women, 77%  
reported swelling within 3 years of diagnosis, and the remaining women developed 
symptoms gradually over the subsequent 17 years. Studies vary on the percentages of 
women who develop lymphedema, but they agree that in the majority of women 
lymphedema develops more often during the first three years after surgery, and incidence 
tapers in years to come. 
Lymphedema occurs when arterial capillary filtration exceeds lymphatic transport 
capacity. Fluid is continuously filtered from the capillaries into the interstitium. Ninety 
percent of the fluid is reabsorbed into the venous system; ten percent of that fluid is 
filtered and transported from the interstitium by the lymphatic system back to the 
vascular system (Ridner, 2002). Transport capacity is diminished by removal or 
destruction of lymph nodes. Once there has been an excision and/or radiation to the nodal 
basin, the capacity to transport and filter the lymphatic load is curtailed. This results in a 
reduced capacity to transport and filter protein, water, metabolic wastes, viruses and 
bacteria. Any further overloading of the transport capacity has the potential to trigger the 
onset of chronic lymphedema (Schuch, 2001).  Lymphedema is not simply lymphatic 
obstruction; it is a complex sequence of events, and research is needed throughout this 
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evolving process. Evidence suggests hemodynamic factors, if not causal, may contribute 
to lymphedema (Mortimer, 1998). In addition to diminished transport capacity, studies 
have shown that there is an increase in blood flow to the edematous arm when compared 
to the non-edematous arm. This may lead to increased capillary filtration into an arm with 
impaired lymphatic transport capacity (Bates, Levick & Mortimer, 1994; Stanton, Levick 
& Mortimer,1996). Studies have identified hypertension as a possible contributing factor 
to lymphedema; and treatment for hypertension was found to be a protective factor 
(Bates, et al., 1994; Deo, et al., 2004; Engel, Kerr, Shlesinger-Raab, Sauer, & Holzel, 
2003; Geller, Vecek, O’Brien, & Secker-Waler, 2003; Herd-Smith, Russo, Grazia 
Muraca, Rosselli Del Turco, & Cardona, 2001).  One limitation to these studies is that, 
like the definition of lymphedema, the definition of hypertension varies among studies. 
Consideration of the damage to the lymphatic system along with hemodynamic factors is 
an important step to understanding potential risk factors of lymphedema after treatment 
for breast cancer (Ridner, 2002). 
Published clinical practice guidelines for lymphedema offer suggestions to 
prevent lymphedema based on interventions that make clinical sense, although the 
evidence supporting their suggestions is limited and anecdotal (Harris, Hugi, Olivotto, & 
Levine, 2001). The National Lymphedema Network (NLN) has published prevention 
guidelines; these guidelines are a listing of prudent advice based on a basic understanding 
of the lymphatic system (Schuch, 2001). The NLN guidelines have been strengthened and 
updated since they were first published in 1990 to reflect the current level of knowledge 
in the world of lymphology. However, it is noted that the lack of evidence-based data 
continues to make it difficult to justify these guidelines (Thiadens, 2005). 
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There have been no randomized controlled trials or cohort studies to provide 
evidence based interventions designed specifically to prevent lymphedema after breast 
cancer treatment (Erickson, Pearson, Ganz, Adams & Kahn, 2001). In the absence of 
evidence-based prevention measures, NLN’s risk reduction guidelines should be included 
in patient teaching when explaining precautions that may reduce risk of lymphedema 
(Ridner, 2002).  
Problem and Purpose 
After axillary lymph node dissection, secondary upper extremity lymphedema may 
develop, once established, it is a chronic and incurable morbidity of treatment. It is 
imperative for patients to be aware of their lifelong risk of developing lymphedema to 
enable them to make informed decisions (Ridner, 2002). There is a lack of evidence-
based research and interventions to prevent lymphedema after breast cancer surgery. 
Prevention and physical therapy are the focus when teaching patients about lymphedema 
(Muscari, 2004). Health care practitioners find it difficult to provide patients with 
estimates of their chances of developing lymphedema or when lymphedema can most 
likely occur (Erickson et al., 2002).  
The presence of hypertension has been shown to be a significant factor in the 
development of lymphedema after treatment for breast cancer (Deo, et al., 2004; Engel, et 
al. 2003; Geller, et al., 2003). However, standards for the definition of hypertension are 
not consistent across studies. The purpose of this study was to explore the relationship 
between elevated blood pressure and the development of lymphedema in women treated 
for breast cancer.  
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Research Question 
The following question was the focus of this study: 
Is there a significant difference in the mean systolic blood pressure between two 
matched samples, one with and one without lymphedema, within the first 15 months 
following treatment for breast cancer? 
Hypothesis: Women with a diagnosis of lymphedema will experience an increased 
prevalence of elevated systolic blood pressure compared to a matched sample of women 
without lymphedema. 
Definition of Terms 
Secondary upper extremity lymphedema is defined as the accumulation of lymph 
fluid in the arm and/or hand after surgical removal of lymph nodes and/or radiation 
therapy as treatment for breast cancer. (Cornish et al., 2000).  For the purposes of this 
retrospective chart review, a documented diagnosis of lymphedema evidenced by a 
diagnosis code for lymphedema in the patient chart defined the presence of lymphedema. 
Hypertension is defined by the Seventh Report of the Joint National Committee 
on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure in stages 
Pre hypertension is a systolic BP of 120-139 or a diastolic BP of 80-89; stage 1 
hypertension is a systolic BP of 140-159 or  diastolic BP of  90-99; stage 2 hypertension 
is a systolic  BP of  >160 or a diastolic BP of  >100. Blood pressure is considered 
elevated if systolic BP is increased by 20mmHg or if diastolic BP is increased by 
10mmHg based on the mean of two or more BP readings on each of two or more office 
visits (Chobanian et al., 2003).  
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Significance  
At this time, there is no evidenced-based research available for clinicians to teach 
their patients on prevention of lymphedema. Since lymphedema may occur immediately 
after surgery or later in life, there is a need to teach life-long precautions. These 
precautions require considerable lifestyle modifications for an undefined amount of time. 
Clinicians struggle with standards of care that are not evidence-based and the need to 
teach effective prevention measures (Muscari, 2004). This study may shed light on the 
importance of recognizing elevated blood pressure and controlling hypertension as one 
evidence-based method for preventing or controlling lymphedema. 
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Chapter II 
Review of Literature 
 This chapter reviews and summarizes current knowledge of the incidence, 
prevalence, diagnosis, time of onset, and risk factors of secondary upper extremity 
lymphedema following treatment for breast cancer. This review of literature focuses on 
type of cancer treatment and co-morbidities which are risk factors for developing breast 
cancer related upper extremity lymphedema. The chapter concludes by reviewing 
elevations in blood pressure as a possible modifiable risk factor in need of further study. 
Incidence and Prevalence of Lymphedema 
In a review of literature from 1985 to 1999, Erickson, Pearson, Ganz, Adams, and 
Kahn (2001) reported  incidence of lymphedema varied with surgical procedure, breast 
cancer therapy, definition of lymphedema, and time from surgery to onset of 
lymphedema. Estimates of the incidence of lymphedema range from 6% to 86 % (Clark, 
Sitzia, & Harlow, 2005). The American Cancer Society estimates that there will be 
212,920 new cases of invasive breast cancer diagnosed in 2006 (American Cancer 
Society [ACS], 2005).  At best, 12,775 of those women will develop lymphedema and at 
worst, 183,111 will develop lymphedema after treatment for breast cancer. In a 
retrospective analysis conducted over a 15 month time frame, Deo et al. (2004) found the 
prevalence of clinically significant lymphedema was 13.4% for patients who were treated 
with surgery alone and 42.4% for patients treated with surgery and radiation.  
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Diagnosis of Lymphedema 
The diagnosis of lymphedema is generally made by medical history and physical 
exam. There are a wide range of subjective and objective evaluation methods; the 
methods most used are patient questionnaire, sequential circumferential measurement and 
volume measurement. A limitation of the research reviewed is that there is no 
standardization of measurement or consistency in methods of measurement (Erikson et 
al., 2001). 
Subjective Measurements  
Patient reported symptoms and questionnaires are often used to determine the 
presence and complications of lymphedema. Questionnaires were used by researchers in 
a study to assess the nature and severity of arm complaints as well as to determine if they 
interfere with activities of daily life, psychosocial functioning, and quality of life 
(Ververs et al. 2001). Considerable thought and planning to test and validate 
questionnaires is necessary (Norman, Miller, Erikson, Norman, & McCorkle, 2001). A 
number of studies have used questionnaires along with telephone interviews; co-
morbidities were not the focus of these methods. Qualities of life, impact on daily life, 
and severity of symptoms have been measured. Questions on co-morbidities present at 
the time of onset of lymphedema, specifically hypertension, were not analyzed in these 
questionnaires (Vevers et al., 2001; Engle et al., 2003; Goffman et al., 2004). 
Objective Measurements  
Objective measures have varied as well, most studies have relied on sequential 
circumferential arm measurements because this is a simple, cost effective, reproducible 
and reliable method to define and determine the presence of lymphedema. However, 
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quantification varies among studies. In one study the definition was determined to be a 
finding of greater than or equal to a two centimeters difference in the circumference of 
the affected and non-affected arm (Armer & Fu, 2005). In another, the difference of three 
centimeters between arms (Deo et al., 2004), and still another considered a difference of 
greater than five percent between arms (Herd-Smith, 2001). Points of measurement also 
have varied, circumference measurements have been taken at various intervals from the 
hand to the shoulder. Some used anatomical points on the arm, others measured from 
anatomical points on the arm. The simplest method used the elbow as the point of 
reference and recorded three areas to be measured at predetermined distances from the 
elbow (Petrek et al., 2001). 
Because of differences in the methods used to determine the presence of 
lymphedema, the numbers have varied widely, and prevalence of lymphedema after 
treatment for breast cancer is difficult to determine. In addition, distribution of swelling 
in the affected arm is often uneven and can develop anywhere between the shoulder and 
the hand (Stanton et al., 2001). The definition of secondary lymphedema after treatment 
for breast cancer varies among studies; in some studies subjective findings are enough 
while in others they are accompanied by objective findings.  
Time of Onset of Lymphedema 
Four patterns of acute lymphedema have been identified: the first, occurring 
within a few days of surgery; the second, six to eight weeks postoperatively; the third, 
after insect bite or burn; and the fourth, is usually insidious having a variable onset about 
eighteen to twenty-four months after surgery (Lymphedema PDQ, 2005). In an effort to 
identify prevalence, time of onset, and associated predictive factors related to 
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lymphedema, Petrek, Senie, Peter, and Rosen (2001) conducted a cohort study spanning a 
20 year time period. They found that the interval to onset of lymphedema symptoms was 
reported by 77% of the cohort to have occurred within the first three years after 
treatment. The subsequent rate was 1% per year. Herd-Smith, et al. (2001) found that the 
cumulative probability of lymphedema reached 10% in the two years following surgery. 
Results of a cohort study conducted over an eight year time frame by Geller et al. (2003) 
estimated a cumulative incidence of lymphedema at one year to be 18% and 35% at two 
years. They compared their findings with those of Kiel and Rademaker  who found a 
cumulative incidence of 8% at one year and 35% at 20 months follow-up.  
Risk Factors for Lymphedema 
Surgery and Radiation Therapy  
Surgery and radiation therapy are the main known causative factors for 
lymphedema following treatment for breast cancer. A review of literature from 1985 to 
1999 showed that axillary node dissection and/or axillary radiation therapy were found to 
carry the highest risk for lymphedema as well as pain, paresthesias, weakness, and 
impaired shoulder function (Erickson, et al., 2001). In a retrospective cohort study over a 
three year time period no patient with fewer than five nodes removed developed arm 
edema (Goffman, et al., 2004).  
Co-morbidities  
 Co-morbidities have emerged as significant risk factor for lymphedema following 
treatment for breast cancer. Co-morbidities focused on by clinical studies have been 
obesity, diabetes, and hypertension; research has identified treatment for hypertension to 
be a protective factor.  Geller et al. (2003) noted significant decreased risk of arm 
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swelling among women who were on treatment for hypertension. Bohler et al. (1992) 
noted that the incidence of lymphedema after treatment with axillary surgery and 
irradiation was 35% among patients with normal blood pressure or controlled 
hypertension,  and 61 percent for patients with hypertension (p<0.005). Engle et al. 
(2003) found that hypertension and diabetes were significant contributors to lymphedema 
(p<0.003). Petrek et al. (2001) collected data on the presence or absence of co-
morbidities. The two most common chronic illnesses of the cohort were diabetes mellitus 
11% and hypertension 17.5%; no mention of how chronic illness effects risk of 
lymphedema was made. 
Elevated Blood Pressure as a Modifiable Risk Factor 
Studies have shown that hypertension may be a risk factor for lymphedema and 
hypertension is a prevalent health problem among women in the United States. 
Cardiovascular disease (CVD) claims the lives of more women than breast cancer. A 
Harris poll commissioned by the American Heart Association in 2003 revealed that only 
13 percent of American women believed that CVD presents the greatest health threat to 
women (American Heart Association [AHA], 2004). The pathophysiology of the 
development of lymphedema involves additional mechanisms other than lymphatic 
damage (Bates et al., 1994).  Lymphedema depends on fluid capillary filtration to the 
affected arm as well as the inability to transport fluid due to removal and/or destruction 
of lymph nodes. Studies have indicated that angiogenesis occurs in the skin of the 
affected arm after treatment for breast cancer and that increased capillary surface area for 
filtration could result in an increase in fluid load on an already compromised lymph 
drainage system (Stanton, Levick, &  Mortimer, 1997). Angiogenesis has also been 
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hypothesized as a contributing factor (Stanton et al., 2001) Consideration of the 
hemodynamic factors as well as the damage to the lymphatic system is key in 
understanding the pathophysiology of lymphedema (Ridner, 2002) 
Definition of Elevated Blood Pressure and Hypertension 
The Seventh Report of the Joint National Committee on Prevention, Detection, 
Evaluation and Treatment of High Blood Pressure (JNC VII) was commissioned in 
response to the need to update guidelines on hypertension. The new guideline added pre-
hypertension as a category for the classification and management of hypertension. A 
systolic blood pressure of 120 to 139 mmHg or diastolic blood pressure of  80 to 89 
mmHg are now considered pre-hypertension. If blood pressure is > 20/10mmHg above 
goal blood pressure, consideration should be given to initiating therapy. It is estimated 
that among people age 18 to 74 years old, 30% are unaware they have hypertension 
(Chobanian, et. al, 2003).  
Prevalence of Hypertension 
In the United States hypertension (HTN) is the most common primary diagnosis 
comprising 35 million offices visits in the year 2000.  In 2003 CVD was the first listed 
diagnosis of 3,196,000 women discharged (both alive and dead) from short-stay 
hospitals. Of those women, 299,000 women were diagnosed with HTN and 31,065 
women died from HTN.  Before age 45 the incidence of HTN is greater in men than 
women; by age 45 to 54 this trend changes. In 2003, women represented 53.1 percent of 
deaths related to CVD in the United States (AHA, 2004). Between the years of 1999 and 
2002, the U.S. Department of Health and Human Services estimated the percentage of  
women with elevated blood pressure or who are taking antihypertensive medication by 
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age group as; 15.1% among ages 35-44, 31.8% among ages 45-54, 53.9% among ages 
55-64, 72.7% among ages 65-74; and women age 75 and over have an 83.1% chance of 
having elevated blood pressure or will be taking antihypertensive medications(AHA, 
2004). It is logical to assume that in many subjects’ elevations in blood pressure and the 
diagnosis of true hypertension is missed by clinical blood pressure assessment alone. 
Studies show ambulatory blood pressure monitoring to be effective in determining 
hypertension. Conversely, elevations in blood pressure and heart rate during a clinic visit 
(white coat hypertension) may be misinterpreted (Paolo et al., 2004). A limitation of the 
studies reviewed was that ambulatory blood pressure (ABP) is not considered. In future 
prospective studies ABP should be evaluated to detect isolated ambulatory hypertension 
and effects of white coat hypertension. 
Summary 
 Surgery and radiation therapy are the primary insults to the axillary lymphatic 
system and are presumably the root cause of lymphedema by reducing the lymph 
transport capacity. The status of the axillary lymph nodes is an important prognostic 
indicator and is used to direct choices of adjuvant therapy for patients with breast cancer. 
Since there is no cure for lymphedma, the combination of axillary dissection and 
radiotherapy should be avoided when feasible. Although less extensive surgeries have 
been developed such as sentinel lymph node biopsy, if the sentinel nodes are involved 
with disease, complete axillary dissection often follows (NCCN, 2005). The wide 
variation in reported occurrences of lymphedema may be due to varied procedures for 
diagnosing lymphedema (Ridner, 2002). Studies have challenged the assumption of a 
higher prevalence of lymphedema and related symptoms among older versus younger 
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breast cancer survivors. Armer and Fu (2005) found that the occurrence of lymphedema 
was 30.6% for women older than 60 and 41.2% for women younger than 60.  
  Study findings suggest the possibility of hypertension as a modifiable risk factor, 
considering increased venous pressure and increased capillary filtration in an arm that has 
been compromised by the removal or destruction of lymph nodes. The studies reviewed 
showed four significant factors contributed to arm problems: extent of axillary surgery, 
radiation therapy to the axilla, younger age, and co-morbidities, specifically hypertension. 
New guidelines on the definition of hypertension tell us that we need to reevaluate which 
patients we consider to be hypertensive. A Harris poll tells us that women are not 
recognizing hypertension as a condition more dangerous than breast cancer (AHA, 2004). 
The presence of elevations in blood pressure or hypertension is often a secondary concern 
in the shadow of a diagnosis of cancer. The role that treatment for high blood pressure 
may play in protecting women from lymphedema needs further study. This study 
explored elevations in blood pressure as a possible modifiable risk factor for secondary 
upper extremity lymphedema.  
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Chapter III 
Methods 
 This was a retrospective case matched study conducted by chart review. This 
section outlines the research methods used to explore the relationship between elevations 
in blood pressure and the development of secondary upper extremity lymphedema 
following treatment for breast cancer. First, population, sample, characteristics of the 
sample, inclusion and exclusion criteria are described. Second, procedures for collecting 
data are presented. Finally, the method of data analysis is discussed. 
Population, Sample and Setting 
 The target population included medical records of patients treated for breast 
cancer at a National Cancer Institute-designated cancer center located in the southeastern 
United States. The sample consisted of medical records of Stage II and III breast cancer 
patients. All women who met study criteria were evaluated. Those records were then 
matched with medical records of women who had not been diagnosed with lymphedema. 
A sample of 50 women was sought. 
Inclusion Criteria 
Data were collected from charts of patients who had been diagnosed with Stage II 
or III breast cancer and had a lymph node dissection as part of treatment for breast 
cancer. Surgical procedures included were; lumpectomy and/or mastectomy with node 
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dissection of 5 or more lymph nodes, women who had a contra-lateral prophylactic 
mastectomy without lymph node dissection were also included.  
Exclusion Criteria 
 Patients who had had bilateral lymph node sampling or dissection, a prior 
diagnosis of breast cancer, history of prior surgery for breast cancer or benign breast 
disease with a lymph node dissection in the affected arm, metastatic cancer, or have 
developed metastasis during the first three years were excluded from the chart review. 
Patients without complete medical records were not included in this chart review.  
Study Variables 
Data included pre-operative age, systolic blood pressure, and number of lymph 
nodes removed. Interval systolic blood pressure was collected from 1 month up to 15 
month time frame. Charts were matched by age and number of axillary nodes removed.  
Procedures 
 The study plan was approved by the Comprehensive Breast Cancer Program 
Leader and the Moffitt Scientific Review Committee. Following those approvals, the 
proposal was approved by the Institutional Review Board (IRB) of the University of 
South Florida. Waiver of informed consent was given (Appendix A). With the approval 
of the IRB, data collection began.  
A chart review was conducted by the primary investigator over a three week 
period.  No patient names, dates of birth, medical record numbers or other personally 
identifiable information was collected. All records were included that met the 
requirements for the group; within that group, diagnosis codes were used to find women 
with a diagnosis of lymphedema and the group without the diagnosis of lymphedema. 
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Medical records were reviewed at a secure computer terminal at the Moffitt cancer 
research center. Biographic data was reviewed in Power Chart, collected and recorded on 
the bioform. Data were directly entered in to an Excel database and SPSS software was 
used in the analysis of the data.   
Data Analysis 
 The two groups in this study were matched by key characteristics of age and 
number of lymph nodes removed. To determine if there is a difference in mean systolic 
blood pressure between the lymphedema group and the non-lymphedema group a t-test 
was used to compare the means of the systolic blood pressures. 
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Chapter IV 
Results, Discussion and Conclusions 
This chapter presents study findings and discussion of the data.  It begins with an 
initial discussion of demographic data and continues with analysis of data as it relates to 
the research questions.  The chapter concludes with recommendations for further study. 
Results 
Sample 
 The sample consisted of 147 Stage II and III breast cancer patients who were 
surgically treated with axillary lymph node dissection from January 2000 to January 
2003. From that sample 27 patients developed lymphedema within the first 36 months; 19 
of the 27 met the lymphedema group inclusion criteria, these were matched with 18 
patients with no diagnosis of lymphedema. Mean age and number of lymph nodes 
dissected were equivalent between groups(Table 1). 
Table 1. Mean Age and Number of Nodes Removed 
    Mean  Mean Number of 
   n Age SD Nodes Removed Range  SD 
________________________________________________________________________ 
Lymphedema  19 55.6 7.9  17.8  9-27  7.8 
Non-Lymphedema 18 55.8 7.6  18.2  8-33  5.6 
________________________________________________________________________ 
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Stages of Hypertension Among Groups 
The systolic blood pressures for both groups were evaluated for fit into the 
hypertension classifications set by the JNC VII guidelines. Although most patients fit into 
the Pre-HTN classification, some patients in each group were classified as having Stage 1 
or 2 hypertension (Table 2). 
Table 2. Study Groups Hypertension Classification By JNC VII Guidelines 
Lymphedema    Non-Lymphedema 
   Frequency               Percent  Frequency   Percent 
_______________________________________________________________________ 
 
Pre-HTN       17            89.4      14                  77.7 
Stage 1 HTN         1              5.3        2       11.1 
Stage 2 HTN         1              5.3        2       11.1 
Total        19             100       18       99.9 
________________________________________________________________________ 
Systolic Blood Pressure and Lymphedema 
To answer the research question, is there a significant difference in the mean of 
the systolic blood pressures between two matched samples, one with and one without 
lymphedema, systolic blood pressures were compared. Three systolic blood pressures 
documented during three clinic visits at least two months apart were used were used to 
determine if there was a difference between groups. The time frame was from two 
months after lymph node dissection up to 15 months following treatment.  
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Independent t tests were performed to determine the mean systolic blood pressure 
differences between groups. No significant differences were found between the two 
groups (Table 3). 
Table 3. Independent t Test Comparison of Mean Systolic Blood Pressure 
   Lymphedema   Non-Lymphedema 
   n Mean   n Mean  t p 
________________________________________________________________________ 
Systolic #1  19 128.6   18 127.7  .16 .87 
Systolic #2  19 125.4   18 126.5  .16 .87 
Systolic #3  19 124.4   18 130.8  .91 .36 
Mean Systolic  19 126.1   18 128.3  .41 .68 
________________________________________________________________________ 
Discussion 
Sample 
 A limitation of the demographic data was that race was not taken into 
consideration. It is known that African-American women suffer from higher rates of 
hypertension than women of other races (AHA, 2004). The data collection process was 
complicated by the fact that vital signs were not completely documented in the charts and 
in some charts there was no documentation of vital signs at all. For this reason, after 
reviewing charts from the study population of 147 women only 19 out of the available 27 
who qualified for the lymphedema group fit inclusion criteria for this study and only 18 
out of the 110 of the non-lymphedema group had adequate documentation of vitals signs 
for inclusion in this study. The lack of documentation of vital signs may indicate that this 
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is not an area that is scrutinized during patient visits. The assumption of white coat 
hypertension or problems of higher priority may have overshadowed these observations. 
Possibly, because of this the connection between lymphedema and elevated blood 
pressure is not an observation that can be made on a daily basis as a risk factor for 
lymphedema. This study is different from studies reviewed in that it relied on the 
presence of a diagnosis code for lymphedema to identify patients who were diagnosed as 
having developed lymphedema. Although it is a logical assumption that between 
physician documentation and physical therapy provided for lymphedema a diagnosis 
code would be generated; this retrospective method of determining presence of 
lymphedema is only as reliable as physician reports of an existence of lymphedema and 
may not be any more reliable for identifying patients with lymphedema than patient 
questionnaire. 
 Although this was a small sample of patients the two groups were very 
comparable in age and total number of nodes removed. This was a strength of this study. 
A larger sample with better representation may have had a different more generalizable 
outcome. 
Stages of Hypertension Among Groups 
 Stages of hypertension were also very similar among groups. Both groups had the 
largest portion of patients in the Pre-HTN stage. It is estimated that among people age 18 
to 74 years old, 30% are unaware they have hypertension and since the latest JCN VII 
guidelines were published many clinicians may not consider the new pre-HTN stage with 
a systolic range from 120 to 139 mmHg to be of concern during medical oncology clinic 
visits when taking patient anxiety into consideration. These two misconceptions may lead 
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to underestimating the significance of elevated blood pressure and hypertension in 
relation to the onset of lymphedema. Another possible explanation for this finding could 
be that the women were taking antihypertensive medications. A limitation of this study 
was that medication data were not available.  
Systolic Blood Pressure and Lymphedema 
 The results show that there is no significant difference in systolic blood pressure 
between the two groups.  Previous studies have indicated a relationship between 
hypertension and lymphedema (Bates, et al., 1994; Deo, et al., 2004; Engel, Kerr, 
Shlesinger-Raab, Sauer, & Holzel, 2003; Geller, Vecek, O’Brien, & Secker-Waler, 2003; 
Herd-Smith, Russo, Grazia Muraca, Rosselli Del Turco, & Cardona, 2001). The lack of 
relationship in this study may be due to the small sample size that was dictated by the 
availability of data on the variable of systolic blood pressure. The two groups consisted 
of women between the ages of 55 and 56 years old. This is a very narrow age group, and 
does not represent the spectrum of age groups in the study sample. This group is not 
generalizable to the study population of stage II and III breast cancer patients. 
The American Heart Association estimates that among ages 55 to 64, 53.9% of 
women will have a problem with elevated blood pressure or will be taking 
antihypertensive medication. In this study 89% of the lymphedema groups were in the 
pre-HTN stage and there was one patient in Stage I and II HTN. In the non-lymphedema 
group 77% of the patients were in the pre-HTN group and 2 each had stage I and II HTN 
(Chobanian et al., 2003). This patient sample has a higher percent than estimated by the 
American Heart Association.  
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Conclusions 
 The results show no difference in systolic blood pressures between groups 
however, this preliminary study had many limitations, such as adequate retrospective data 
availability. The ages of the women available for inclusion in the two groups were very 
similar; this was a strength of the study. Further investigation into the hemodynamic 
factors as one of the modifiable risk factor for lymphedema is warranted.  
Recommendations for Future Research 
  Future prospective studies should include standardized measures for presence and 
severity of lymphedema, use of JNC VII stages of blood pressure, and better 
documentation to determine time of onset of lymphedema so that it can be compared to 
the time of occurrence of elevated blood pressure. Future prospective studies may help 
shed light on the relationship between elevated blood pressure and treatment for 
hypertension on the occurrence of lymphedema after axillary lymph node dissection. 
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